Company profile
Angitia Biopharmaceuticals company profile
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
Business identity
- Website
- https://angitiabio.com
- Contact email
- [email protected]
- Phone number
- 206-232-9813
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 51-100 employees
- Revenue range
- $1M-$10M
- Founded
- 2018-01-01, Year
Headquarters
- Headquarters
- Westlake Village, California, United States
- Postal code
- 91361
- Country code
- US
- Continent
- North America